DuPont de Nemours (NYSE:DD) Price Target Raised to $176.00

Key Points

• Citigroup raised its DuPont price target to $176 from $162 and maintained a “buy” rating, implying 16.44% upside from the stock’s reported $151.15 price.
• DuPont beat quarterly expectations, reporting EPS of $2.09 versus $1.87 expected and revenue of $1.87 billion versus $1.84 billion; revenue increased 4.1% year over year.
• Analyst views are generally positive but mixed: the stock has a “Moderate Buy” consensus rating and an average target of $164.12, with 12 Buy, five Hold, and one Sell rating.

DuPont de Nemours (NYSE:DD - Get Free Report) had its target price lifted by research analysts at Citigroup from $162.00 to $176.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the basic materials company's stock. Citigroup's price target would suggest a potential upside of 16.44% from the stock's current price.

Several other analysts have also issued reports on DD. Zacks Research lowered DuPont de Nemours from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 17th. Royal Bank Of Canada decreased their target price on DuPont de Nemours from $176.00 to $160.00 and set an "outperform" rating on the stock in a report on Thursday, October 15th. Weiss Ratings restated a "sell (d+)" rating on shares of DuPont de Nemours in a research note on Friday. The Goldman Sachs Group dropped their price target on DuPont de Nemours from $159.00 to $153.00 and set a "neutral" rating on the stock in a research note on Wednesday, September 30th. Finally, JPMorgan Chase & Co. downgraded DuPont de Nemours from an "overweight" rating to a "neutral" rating and cut their price target for the company from $172.00 to $145.00 in a report on Friday, October 9th. Twelve investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $164.12.

DuPont de Nemours Stock Performance

Shares of DD traded down $2.31 during midday trading on Wednesday, reaching $151.15. The stock had a trading volume of 2,547,351 shares, compared to its average volume of 1,350,640. The firm has a 50 day simple moving average of $132.64 and a 200-day simple moving average of $138.51. DuPont de Nemours has a one year low of $111.15 and a one year high of $157.98. The firm has a market cap of $20.41 billion, a PE ratio of 335.96, a P/E/G ratio of 1.31 and a beta of 1.06. The company has a current ratio of 2.43, a quick ratio of 1.82 and a debt-to-equity ratio of 0.23.

DuPont de Nemours (NYSE:DD - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The basic materials company reported $2.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.87 by $0.22. DuPont de Nemours had a net margin of 0.67% and a return on equity of 6.92%. The company had revenue of $1.87 billion for the quarter, compared to analysts' expectations of $1.84 billion. During the same period in the prior year, the firm earned $1.09 EPS. DuPont de Nemours's quarterly revenue was up 4.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that DuPont de Nemours will post 7.25 EPS for the current year.

Institutional Investors Weigh In On DuPont de Nemours

A number of institutional investors have recently made changes to their positions in DD. Physician Wealth Advisors Inc. increased its stake in shares of DuPont de Nemours by 223.1% during the third quarter. Physician Wealth Advisors Inc. now owns 210 shares of the basic materials company's stock worth $27,000 after purchasing an additional 145 shares during the period. Elevation Wealth Partners LLC boosted its stake in DuPont de Nemours by 168.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 239 shares of the basic materials company's stock valued at $32,000 after purchasing an additional 150 shares during the period. DHJJ Financial Advisors Ltd. boosted its stake in DuPont de Nemours by 150.0% in the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 250 shares of the basic materials company's stock valued at $32,000 after purchasing an additional 150 shares during the period. Bangor Savings Bank acquired a new position in DuPont de Nemours in the 3rd quarter valued at $36,000. Finally, Compass Wealth Management LLC acquired a new position in DuPont de Nemours in the 3rd quarter valued at $39,000. Institutional investors own 73.96% of the company's stock.

Trending Headlines about DuPont de Nemours

Here are the key news stories impacting DuPont de Nemours this week:

• Positive Sentiment: Q3 results topped expectations: DuPont reported adjusted EPS of $2.09 versus the $1.87 consensus and revenue of about $1.87 billion versus $1.84 billion expected. Sales rose 4% year over year, with organic sales up 5%. DuPont Reports Third Quarter 2026 Results
• Positive Sentiment: Raised 2026 guidance: The company increased its full-year outlook again, citing strong demand in healthcare and aerospace. Its earnings release also highlighted robust cash generation, including $341 million in transaction-adjusted free cash flow. DuPont raises full-year profit forecasts on strong healthcare, aerospace demand
• Positive Sentiment: Share repurchases provide additional support: After completing substantial buybacks in Q3, DuPont said it intends to repurchase another $250 million of shares in Q4. DuPont Reports Third Quarter 2026 Results
• Positive Sentiment: Barclays lifted its target: The firm raised its price target from $156 to $176 and reiterated an “overweight” rating, signaling confidence in further upside. Barclays stock recommendations
• Neutral Sentiment: A report highlighted DuPont’s new peptide-purification product, but the available article headline provides limited detail on its expected financial contribution. What Is DuPont Signaling With Its New Peptide Purification Product?

DuPont de Nemours Company Profile

DuPont de Nemours, Inc is a diversified science and technology company that develops engineered materials and specialty products for industrial and consumer markets. Its offerings are used in applications including electronics, semiconductor manufacturing, water purification, transportation, construction, healthcare, and worker and consumer protection.

The company's product portfolio has historically included high-performance films, resins, adhesives, engineered polymers, specialty fibers, protective materials, water-treatment membranes, and filtration technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.